Genmab — September 2019
-
Så mangler vi bare at køberne bliver insisterende igen.
-
Ja, spørgsmålet er om de er ved at opbygge en ny/større position eller om de bare forsvarer deres nuværende position og så er kommet lige over grænsen igen.
-
Tvivlert på shorterne gå tvinge Genmab ud af nuværende lange trendkanal fra Nov. 2018 uden mega negativt nyt. Lad dem bare komme til for det giver trods alt også lidt brændstof til yderligere kursstigning når de indser Genmab har fat i den lange ende
-
TA på Genmab fra HH: http://www.proinvestor.com/debat/77147
-
amazing what pipeline news can do...
-
Nyt studie: The purpose of this study is to identify recommended Phase 2 doses (RP2Ds) and schedules for each combination (combination 1: daratumumab and JNJ-64407564 [anti-GPRC5DxCD3] or combination 2: daratumumab and JNJ-64007957 [anti-BCMAxCD3]) and to characterize the safety of each RP2D for each combination
-
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind